Blood Proteins Patents (Class 435/69.6)
-
Publication number: 20150080556Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: November 24, 2014Publication date: March 19, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Georg FERTIG, Alexander FIDLER, Klaus KALUZA, Marlene THOMAS, Carola RIES, Stefan SEEBER
-
Publication number: 20150079084Abstract: The invention provides bispecific fusion proteins that inhibit activation of complement pathway and vascular endothelial growth factor (VEGF) pathway and methods for using these fusion proteins.Type: ApplicationFiled: November 30, 2012Publication date: March 19, 2015Inventors: Jeng-Horng Her, Huang-Tsu Chen
-
Patent number: 8980583Abstract: The present invention provides non-human mammalian cell lines that are deficient in CMP-Neu5Ac hydroxylase (Cmah) and/or glycoprotein alpha-1,3-galactosyltransferase (Ggta1). Also provided are methods for using the cells disclosed herein for producing recombinant proteins with human-like patterns of glycosylation.Type: GrantFiled: June 29, 2012Date of Patent: March 17, 2015Assignee: Sigma-Aldrich Co. LLCInventors: Nan Lin, Henry J. George, Joaquina Mascarenhas, Trevor N. Collingwood, Kevin J. Kayser, Katherine Achtien
-
Publication number: 20150072368Abstract: Novel transcription units that may be used in expression vectors. The transcription unit allow antibodies to be produced whose gain in productivity is not linked to a particular antigenic target antibody and therefore by extrapolation to a given recombinant protein, nor linked to the culture medium.Type: ApplicationFiled: February 8, 2013Publication date: March 12, 2015Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIESInventors: Alexandre Fontayne, François Coutard
-
Publication number: 20150071883Abstract: The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.Type: ApplicationFiled: September 10, 2014Publication date: March 12, 2015Inventor: Peter Cameron Colosi
-
Publication number: 20150071923Abstract: Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.Type: ApplicationFiled: September 12, 2014Publication date: March 12, 2015Inventors: Ge Wei, Gregory I. Frost, H. Michael Shepard, Christopher D. Thanos
-
Publication number: 20150064182Abstract: The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.Type: ApplicationFiled: August 13, 2014Publication date: March 5, 2015Applicant: Ablynx N.V.Inventors: Karen Silence, Marc Jozef Lauwereys, Torsten Dreier
-
Publication number: 20150064179Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (1L-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.Type: ApplicationFiled: August 29, 2014Publication date: March 5, 2015Inventors: FRANK OSTERROTH, CHRISTOPH UHEREK, CHRISTOPH BRUECHER, PETER RÖTTGEN, BENJAMIN DAELKEN, ANDRÉ ENGLING, CHANTAL ZUBER, NIKLAS CZELOTH, ANDREA WARTENBERG-DEMAND, MARCUS GUTSCHER, JUDITH WESSELS-KRANZ
-
Publication number: 20150064746Abstract: Herein is reported a method for the recombinant production of a polypeptide, which comprises the tripeptide QKK, characterized in that the method comprises the step of recovering the polypeptide from the cells or the cultivation medium of a cultivation of a cell comprising a nucleic acid encoding the polypeptide and thereby producing the polypeptide, whereby the tripeptide QKK comprised in the polypeptide is encoded by the oligonucleotide cag aaa aaa or the oligonucleotide caa aag aaa.Type: ApplicationFiled: August 29, 2014Publication date: March 5, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Adelbert Grossmann, Friederike Hesse, Erhard Kopetzki, Wilma Lau, Christian Schantz
-
Publication number: 20150064725Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful for production of proteins.Type: ApplicationFiled: November 7, 2014Publication date: March 5, 2015Inventors: Jason P. Schrum, Gregory J. Sieczkiewicz, Kenechi Ejebe, Sayda M. Elbashir
-
Publication number: 20150065690Abstract: The present invention relates to modified Fc regions of antibodies, and uses thereof, such as in antibodies that contain an Fc region of the present invention.Type: ApplicationFiled: April 26, 2013Publication date: March 5, 2015Inventors: Gerhard Frey, Jay M. Short, Hwai Wen Chang
-
Publication number: 20150064236Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.Type: ApplicationFiled: March 9, 2013Publication date: March 5, 2015Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
-
Patent number: 8969524Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.Type: GrantFiled: October 27, 2011Date of Patent: March 3, 2015Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
-
Publication number: 20150056210Abstract: The present invention relates to an antibody, recombinant or synthetic antigen-binding fragments thereof able to recognise and bind an epitope comprised in the spacer domain of ADAMTS-5, nucleic acid and expression vector encoding the same, method of production and uses thereof.Type: ApplicationFiled: April 12, 2013Publication date: February 26, 2015Inventors: Riccardo Chiusaroli, Michela Visintin, Gianfranco Caselli, Lucio Claudio Rovati
-
Publication number: 20150056654Abstract: A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilised aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons.Type: ApplicationFiled: July 14, 2014Publication date: February 26, 2015Inventors: Hendrik Van Urk, David John Mead, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michael Gaston Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Darrell Sleep, Jean-luc Bernard Veron
-
Publication number: 20150057436Abstract: The invention relates to novel humanized antibodies derived from the conventional antibody repertoire of species in the family Camelidae.Type: ApplicationFiled: July 28, 2014Publication date: February 26, 2015Applicant: arGEN-X BVInventors: Torsten DREIER, Johannes Joseph Wilhelmus DE HAARD
-
Publication number: 20150056220Abstract: The present disclosure relates to immunoglobulins and immunoglobulin conjugates with reduced oligomerization and efficient labeling and compositions, methods of generating such immunoglobulins and immunoglobulin conjugates and methods of using such immunoglobulin conjugates particularly in the treatment and prevention of disease.Type: ApplicationFiled: August 1, 2014Publication date: February 26, 2015Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, NOVARTIS AGInventors: Naresh CHENNAMSETTY, Bernhard HELK, Veysel KAYSER, Bernhardt TROUT, Vladimir VOYNOV
-
Publication number: 20150056189Abstract: Provided is a pharmaceutical composition for the treatment and/or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: ApplicationFiled: March 29, 2013Publication date: February 26, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Takako Kimura, Hironari Shimizu
-
Publication number: 20150057437Abstract: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.Type: ApplicationFiled: October 17, 2014Publication date: February 26, 2015Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: NOBUAKI TAKAHASHI, TORU MIURA, YOSHINORI KITAGAWA, AKI MATSUSHIMA
-
Publication number: 20150056202Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.Type: ApplicationFiled: March 25, 2014Publication date: February 26, 2015Inventors: Chengbin Wu, Tariq Ghayur, Richard W. Dixon, Jochen G. Salfeld
-
Publication number: 20150056206Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.Type: ApplicationFiled: September 5, 2014Publication date: February 26, 2015Inventor: Hongxing ZHOU
-
Publication number: 20150056656Abstract: Herein is reported a method for the recombinant production of a polypeptide, which comprises the dipeptide AR, characterized in that the method comprises the recovering of the polypeptide from the cells or the cultivation medium of a cultivation of a cell comprising a nucleic acid encoding the polypeptide and thereby producing the polypeptide, whereby the dipeptide AR comprised in the polypeptide is encoded by the oligonucleotide gca cgt, or the oligonucleotide gcg cgt, or the oligonucleotide gcc cgt.Type: ApplicationFiled: August 29, 2014Publication date: February 26, 2015Applicant: HOFFMANN-LA ROCHE INC.Inventors: Adelbert Grossmann, Friederike Hesse, Erhard Kopetzki, Wilma Lau, Christian Schantz
-
Publication number: 20150056182Abstract: The present inventors discovered that by forming a large immune complex comprising antigens containing two or more antigenic binding units (epitopes) and two or more antigen-binding molecules (for example, antibodies), elimination from the plasma of the antigens containing two or more antigenic binding units can be accelerated. Moreover, they found that by using this characteristic and by further using antigen-binding molecules having an ion-dependent antigen-binding activity, elimination of the antigens can further be accelerated and the above problem can be solved.Type: ApplicationFiled: November 30, 2012Publication date: February 26, 2015Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Naoka Hironiwa
-
Publication number: 20150056657Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.Type: ApplicationFiled: September 3, 2014Publication date: February 26, 2015Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Daniel Fleischanderl, Gregor Bramberger
-
Publication number: 20150056655Abstract: The invention relates to an expression construct for the expression of polypeptides in host cells using alternative splicing. The expression construct can be used for the expression of polypeptides such as antibodies, antibody fragments and bispecific antibodies by expressing the gene products required for protein expression at the ratio leading to the highest titres or the best product quality profile.Type: ApplicationFiled: August 6, 2014Publication date: February 26, 2015Inventors: Christel AEBISCHER-GUMY, Martin Bertschinger, Pierre Moretti
-
Publication number: 20150056211Abstract: Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.Type: ApplicationFiled: July 28, 2014Publication date: February 26, 2015Inventors: ROTHE MIKE, NORBERT PRENZEL, ERIC BORGES, THORE HETTMANN, ESTHER ZWICK-WALLASCH
-
Patent number: 8962278Abstract: Provided are oligonucleotides for isolating human antibody cDNAs from cells or cell lines, such as hybridomas. The invention also provides cDNAs that encode at least one provided CDR of a heavy chain or a light chain of a human monoclonal antibody that binds to B. anthracis protective antigen; and cDNAs that encode at least one provided CDR of a heavy chain or a light chain of a human monoclonal antibody that binds to B. anthracis lethal factor. The invention further provides expression vectors that contain one or more cDNAs isolated according to the methods of the invention, host cells expressing one or more inventive cDNAs, and transgenic plants and animals that express one or more inventive cDNAs. In certain embodiments of the invention the expression system is a plant-based expression system. The invention further provides antibody compositions comprising one or more antibodies produced by expressing a cDNA isolated according to the methods of the invention in a suitable expression system.Type: GrantFiled: August 3, 2006Date of Patent: February 24, 2015Assignee: iBio Inc.Inventors: Vidadi Yusibov, Vadim Mett, Anna Hull
-
Publication number: 20150050693Abstract: The present invention relates to methods for modulating the glycosylation profile of recombinantly-expressed proteins. In particular, the present invention relates to methods of controlling the galactosylation profile of recombinantly-expressed proteins by supplementing production medium, e.g., a hydrolysate-based or a chemically defined medium, with manganese and/or D-galactose.Type: ApplicationFiled: September 22, 2014Publication date: February 19, 2015Inventors: Cornelia Bengea, Lisa M. Rives
-
Publication number: 20150050269Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.Type: ApplicationFiled: September 28, 2012Publication date: February 19, 2015Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Atsuhiko Maeda, Shigero Tamba, Takehisa Kitazawa, Takeshi Baba, Yoshinao Ruike, Junichi Nezu
-
Publication number: 20150050273Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.Type: ApplicationFiled: July 31, 2014Publication date: February 19, 2015Inventors: Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
-
Publication number: 20150050270Abstract: The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.Type: ApplicationFiled: March 15, 2013Publication date: February 19, 2015Applicant: SANOFIInventors: Han Li, Dorothea Kominos, Jie Zhang, Alla Pritzker, Matthew Davison, Nicolas Baurin, Govindan Subramanian, Xin Chen
-
Patent number: 8956832Abstract: Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.Type: GrantFiled: July 2, 2013Date of Patent: February 17, 2015Assignee: Morphotek, Inc.Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Wolfgang Ebel, Yuhong Zhou
-
Patent number: 8957194Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: GrantFiled: May 8, 2012Date of Patent: February 17, 2015Assignee: Merck Sharpe & Dohme Corp.Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Timothy McCabe, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Pixley, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Publication number: 20150044208Abstract: The present invention relates to compositions and methods comprising a modified albumin-binding domain to improve the pharmacokinetic properties of therapeutic molecules. The modified peptides show reduced immunogenicity and/or proved solubility. In particular, compositions and methods for enhancing therapeutic potential of protein therapeutics are provided including linking a protein albumin-binding domain, which has been modified to reduce immunogenicity and/or improve solubility, to a therapeutic protein, including therapeutic antibodies, antibody fragments, antibody single domains and/or dimers of antibody single domains. These linked polypeptides can exhibit enhanced serum half life without exacerbated immunogenicity and/or without decreased solubility, and without substantially affecting the specific binding properties of the therapeutic protein.Type: ApplicationFiled: September 19, 2012Publication date: February 12, 2015Applicant: TECHNOPHAGE, INVESTIGAÇÄO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SAInventors: Frederico Nuno Castanheira Aires da Silva, Sofia Volker Côrte-Real, Sara Ferreira Llorente Grancho Lourenço
-
Publication number: 20150044720Abstract: The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.Type: ApplicationFiled: October 3, 2014Publication date: February 12, 2015Applicant: Octapharma AGInventors: Carola Schroeder, Haiyan Ding, Cathleen Wegmann
-
Publication number: 20150044226Abstract: A monoclonal antibody that binds to a phospholipase D4 (PLD4) protein, or a fragment containing an antigen-binding region thereof.Type: ApplicationFiled: January 31, 2013Publication date: February 12, 2015Applicant: SBI Biotech Co., LtdInventors: Minkwon Cho, Tomohide Yamazaki, Mayuki Endo, Koji Ishida
-
Publication number: 20150044214Abstract: The present invention relates to bispecific, tetravalent antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: April 18, 2014Publication date: February 12, 2015Applicant: HOFFMANN-LA ROCHE, INC.Inventors: Sabine IMHOF-JUNG, Christian KLEIN, Joerg Thomas REGULA, Wolfgang SCHAEFER, Juergen Michael SCHANZER
-
Publication number: 20150044237Abstract: New chimeric molecules involving in their structure, a combination of the extracellular domain (EC) of the FasL protein and a domain enabling oligomerisation of this Fas Ligand (FasL) EC domain, such as the Ig-like (so-called Ig in the following pages) domain of the gp190 receptor for the Leukemia Inhibitory Factor (LIF), or involving in their structure variants of the domains. Also, compositions including the chimeric molecule defined herein and the use of these chimeric molecules especially to trigger cytotoxic activity toward cells sensitive to FasL.Type: ApplicationFiled: October 26, 2012Publication date: February 12, 2015Applicant: Centre National de la Recherche ScientifiqueInventors: Jean-Luc Taupin, Sophie Daburon, Jean-Francois Moreau, Myriam Capone
-
Publication number: 20150044235Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: ApplicationFiled: May 22, 2014Publication date: February 12, 2015Applicant: Amgen Inc.Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, George DOELLGAST (DECEASED), HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
-
Publication number: 20150044215Abstract: Polypeptides are provided that are capable of significantly inhibiting andor neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.Type: ApplicationFiled: March 4, 2013Publication date: February 12, 2015Applicant: Ablynx N.V.Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
-
Publication number: 20150044236Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: ApplicationFiled: May 22, 2014Publication date: February 12, 2015Applicant: AMGEN INC.Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
-
Publication number: 20150047065Abstract: The present invention relates to a binding molecule that specifically binds to two different epitopes of an antigen expressed on tumor cells, wherein the binding molecule comprises: (a) a first binding (poly)peptide that specifically binds to a first epitope of said antigen expressed on tumor cells, wherein said first binding (poly)peptide is a Fyn SH3-derived polypeptide; and (b) a second binding (poly)peptide that specifically binds to a second epitope of said antigen expressed on tumor cells. The present invention further relates to a nucleic acid molecule encoding the binding molecule of the invention, a vector comprising said nucleic acid molecule as well as a host cell or a non-human host transformed with said vector. The invention further relates to a method of producing a binding molecule of the invention as well as to pharmaceutical and diagnostic composition.Type: ApplicationFiled: March 8, 2013Publication date: February 12, 2015Inventors: Simon Brack, Frédéric Mourlane, Isabella Toller, Richard Woods, Julian Bertschinger, Dragan Grabulovski, Babette Schade, Kristina Klupsch, Helen Hachemi
-
Publication number: 20150044722Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: ApplicationFiled: September 4, 2014Publication date: February 12, 2015Inventors: Gilles Bernard TREMBLAY, Mario FILION, Matthew STUIBLE
-
Patent number: 8951516Abstract: This invention relates to the modification of the amino acid sequence of an immunoglobulin molecule at certain key positions within regions of the VH and VL FR and CDR3 domains and/or the CH1 domain which are prone to aggregation. Immunoglobulins modified as described may display improved manufacturability, for example, reduced aggregation propensity and/or increased production levels.Type: GrantFiled: August 20, 2010Date of Patent: February 10, 2015Assignee: Lonza Biologics PLCInventors: Andreas Arnell, Jose Jimenez, Rebecca Michael, Yvette Stallwood, Jesus Zurdo
-
Patent number: 8951755Abstract: The use of VHHs in the preparation of products to provide stability of antibody specificity under destabilizing conditions whereby normally lower eukaryotes or traditional antibodies are killed or inactivated.Type: GrantFiled: March 12, 1999Date of Patent: February 10, 2015Assignee: BAC IP B.V.Inventors: Daniel Convents, Leo G. Frenken, Michael M. Harmsen, Richard H. van der Linden, Cornelis T. Verrips
-
Publication number: 20150037356Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.Type: ApplicationFiled: September 6, 2012Publication date: February 5, 2015Applicants: CAMBRIDGE ENTERPRISE LIMITED, MEDIMMUNE LIMITEDInventors: John Elvin, Catherine Huntington, John Trowsdale, Alexander Barrow, Huan Cao
-
Publication number: 20150037352Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.Type: ApplicationFiled: October 16, 2014Publication date: February 5, 2015Inventors: Zachary Shriver, Karthik Viswanathan, Vidya Subramanian, Sasisekharan Raguram
-
Publication number: 20150037248Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.Type: ApplicationFiled: February 13, 2013Publication date: February 5, 2015Applicant: Agency for Science, Technology and ResearchInventors: Cheng-I Wang, Angeline Goh, Siok Ping Yeo, Alessandra Mortellaro, Subhra Kumar, Florent Ginhoux, Pingyu Zhong
-
Publication number: 20150037842Abstract: The disclosure relates to a Gram negative bacterial cell that is transformed with a nucleic acid molecule that encodes a Gram positive twin-arginine translocase and including methods for the production of polypeptides.Type: ApplicationFiled: February 22, 2013Publication date: February 5, 2015Inventor: Colin Robinson
-
Publication number: 20150037334Abstract: The present invention relates to a binding molecule comprising at least three domains comprised in at least one polypeptide chain, wherein the first binding domain is a binding domain which is capable of binding to a cell surface molecule on a target cell, the second binding domain is a binding domain which is capable of binding to the T cell CD3 receptor complex, and the third domain is a binding domain which is capable of binding to serum albumin, wherein said third domain is positioned at the C-terminus of said second domain. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.Type: ApplicationFiled: March 1, 2013Publication date: February 5, 2015Inventors: Peter Kufer, Tobias Raum, Ralf Lutterbuese, Patrick Hoffmann, Markus Muenz, Johannes Brozy, Majk Kvesic